Health Care Equipment

LIFETECH SCI

LIFETECH SCI released FY2025 Q3 earnings on March 31, 2026 (BJT) with actual revenue of HKD 378.82 M and EPS of HKD 0.0108

LIFETECH SCI released FY2025 9 Months Earnings on March 31, 2026 (BJT) with actual revenue of HKD 1.112 B and EPS of HKD 0.0246

LIFETECH SCI released FY2025 earnings on March 31 During-Market (BJT), actual revenue HKD 1.497 B (forecast HKD 1.973 B), actual EPS HKD 0.036 (forecast HKD 0.1)

LIFETECH SCI released FY2025 Q4 earnings on March 31 During-Market (BJT), actual revenue HKD 385.36 M, actual EPS HKD 0.011

LIFETECH SCI to release FY2025 earnings on March 31, 2026, during market hours (BJT), with forecast revenue of HKD 1.938 B and EPS of HKD 0.0982

XianJian Tech's CSTM Stent System Enters China's NMPA Innovative Medical Device Special Review Program

Xian-Jian Technology's G-iliacTM Pro Iliac Artery Stent-Graft System Approved by National Medical Products Administration

XianJian Technology's G-BranchTM Thoracoabdominal Aortic Stent Graft System Approved by China's NMPA

Xian-Janssen Announces Results of Phase II and III Clinical Trials for IBS® Coronary Stent

LIFETECH SCI released FY2025 Q1 earnings on August 29, 2025 (BJT) with actual revenue of HKD 362.37 M and EPS of HKD 0.0067

LIFETECH SCI released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), Actual Revenue: HKD 732.7 M, Actual EPS: HKD 0.0137

LIFETECH SCI released FY2025 Q2 earnings on August 29 During-Market BJT, actual revenue HKD 370.34 M, actual EPS HKD 0.0069

Conous Medical's Nickel-Titanium Atrial Septal Defect Occluder Enters NMPA Innovative Medical Device Special Review Program

LIFETECH SCI to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Sino-Scientech Strategic Investment in Jianhu Medical and Strategic Partnership Agreement

Sinocare Invests in Suzhou Affector MedTech Strategically

Mindray Biomedical Invests in Jianhu Medical

XianJian Technology's Innovative Aortic In-Situ Fenestration Branch Reconstruction Product Approved for Market

XianJianTech’s Aortic Arch Stent System Approved by NMPA

XianJian Technology's Aortic Arch Stent System Approved by NMPA

I.CENTURY HLDG

RIVERINE CHINA

CHINA CBS INTL

KOS TALENT GP

NEW AMANTE

NATURE ENERGY T

REDCO HEALTHY

C&N HOLDINGS

CROSSTEC

ZXZN QI-HOUSE

01302

Star Sports Medicine's shares soared 118% in their Hong Kong debut, reaching a high of HK$299 from an IPO price of HK$98.50. The company raised HK$829.6 million, with retail subscriptions exceeding 7,823 times. This debut continues a trend of strong performances in Hong Kong listings, particularly in the healthcare sector, driven by rising demand for medical devices among China's ageing population. Star Sports specializes in clinical sports medicine solutions, including implants and surgical instruments.

Businesstimes News

XIZHI TECH-P

SUNMI TECH-W

Star Sports Medicine jumps 118% as Hong Kong debut frenzy extends

159898

562600

159883

Star Sports Medicine Co. Ltd. performed exceptionally well in its initial public offering (IPO), with its stock price tripling at the start of trading and ultimately rising 132% at midday. The company sold 8.42 million shares at HKD 98.50 each, raising a net income of HKD 758 million (USD 97 million). The public offering for local Hong Kong investors was oversubscribed more than 7,800 times, while the international offering was oversubscribed 9.4 times. Star Sports Medicine is the fourth largest supplier of sports medicine implants and equipment in China, expected to hold approximately 6.5% market share in 2024

BambooWorks

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

BRIEF: Star Sports Medicine doubles in heavily oversubscribed IPO

516500

516930

159849

Shares of Star Sports Medicine surged 204% in their Hong Kong debut, reaching HK$299 from an IPO price of HK$98.50. The company raised HK$829.6 million, with retail subscriptions exceeding 7,823 times. This debut continues a trend of strong first-day performances in Hong Kong, particularly in the healthcare sector, where demand for medical devices is rising due to China's ageing population. The average first-day gain for listings over US$100 million this year is 42.3%.

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Star Sports Medicine jumps 204% as Hong Kong debut frenzy extends

LifeTech Scientific Corporation is seeking an extension from the Stock Exchange to restore compliance with Hong Kong Listing Rules after falling below the minimum requirements for independent board representation due to the resignation of an independent non-executive director. The company has been unable to fill the vacancy within the three-month grace period and is facing challenges in sourcing qualified candidates. LifeTech pledges to continue efforts to appoint a suitable candidate and will update the market once governance gaps are resolved, highlighting ongoing governance pressures on smaller issuers.

Tip Ranks

LifeTech Seeks More Time to Restore Independent Board Compliance

LifeTech Scientific Corporation reported a 5.1% revenue growth to RMB1,369.8 million for 2025, driven by increased stent graft sales. However, net profit fell 33.3% to RMB112.4 million due to higher expenses and tax charges. Excluding non-recurring items, underlying net profit rose 24.9% to RMB353.4 million. The company did not declare a final dividend, focusing on reinvestment. The latest analyst rating for the stock (HK:1302) is a Hold with a price target of HK$2.00.

LifeTech Scientific Delivers Revenue Growth but Profit Hit by Non-Recurring Charges in 2025

LIFETECH SCI announced its full-year results for the year ended December last year, with a revenue of RMB 1.37 billion, an increase of 5.1% year-on-year. The net profit was RMB 148 million, a decrease of 33.5% year-on-year; earnings per share were 3.4 cents. No dividend was declared. (ha/)

AASTOCKS

LIFETECH SCI's annual net profit is RMB 148 million, a decrease of 33.5%, and no dividend is declared

01346

02283

As global markets shift, investors are eyeing Asian penny stocks for growth. This article highlights three promising stocks: Lever Style (SEHK:1346) with a market cap of HK$890.67M, Asia Medical and Agricultural Laboratory (SET:AMARC) at THB1.1B, and TK Group (SEHK:2283) valued at HK$2.06B. Each stock shows strong financials and potential for value discovery. Additionally, LifeTech Scientific (SEHK:1302) and United Energy Group (SEHK:467) are noted for their market caps of HK$8.38B and HK$12.41B, respectively, despite facing challenges in earnings and management experience.

Simplywall

LEVER STYLE

TK GROUP HLDG

3 Asian Penny Stocks With Market Caps Under US$2B

LIFETECH SCI(01302.HK)